Figure 5
From: TCR γ4δ1-Engineered αβT Cells Exhibit Effective Antitumor Activity
Antitumor activity of TCRγ4δ1-engineered αβT cells in vivo. Mice were subcutaneously injected with 2 × 106 HepG2 cells in the rear right flank. When tumor volume reached approximately 100 mm3, mock- and TCRγ4δ1-engineered αβT cells were injected intratumorally every 3 d a total of 4 times, and the tumor volume in the right flank of each mouse was measured every 3 d until 30 d. (A) Mice treated with TCRγ4δ1-engineered αβT cells exhibited significant suppression of tumor volume compared with mice treated with mock-engineered αβT cells (P = 0.001). Black arrows indicate the treatment time; each point represents the mean ± SEM, **, P < 0.01. (B) The tumor growth inhibition ratio was estimated. (C) Image of the excised tumors in the experiment evaluating the influences of TCRγ4δ1-engineered αβT cells on antitumor activity in HepG2 tumor-bearing nude mice.